摘要
目的:探讨静脉输液渗透压摩尔浓度存在的问题。方法:通过对6种静脉输液品种的渗透压摩尔浓度进行考察,对发现的问题进行分析。结果:大多数考察样品渗透压摩尔浓度测定结果偏低渗;不同生产企业的同一品种,渗透压摩尔浓度测定结果相差大;同一生产企业不同批次的同一品种,渗透压摩尔浓度测定结果也存在差异。结论:为确保临床用药安全、有效,企业应重视对静脉输液渗透压摩尔浓度的控制,并在质量标准中制订合理的渗透压摩尔浓度限度。
Objective：Discuss problem about osmolality of intravenous transfusions. Methods：Through consideration to osmulality of six species Intravenous transfusions, analyze discoverable problems. Results： Osmolality of majority samples are leaning hypo-osmotic; same species of different produce business, their osmolality have large difference ; different batch samples of same species, same produce business, their osmolality also have difference. Conclusions ： To ensure the safety and utility of clinical medication, pharmaceutical business should reconsolidate the control to osmolality of intravenous transfusions, and formulate reasonable osmolality limit in drug quality specification.
出处
《中国药品标准》
CAS
2010年第5期351-354,共4页
Drug Standards of China
